New ETF Book by Larry Connors - Click here to read more
-- Theresa Dixon has been promoted to Vice President of Government Affairs & Health Economics, where she is responsible for leading the Company's government affairs, health policy and health economics initiatives. Since joining ABH in January 2007, Dixon has spearheaded the development of the Company's industry-leading reimbursement and government affairs team. In her new role, she is charged with continuing to build ABH's government relations capabilities while also developing organizational expertise in health outcomes and comparative effectiveness. Dixon is a 15-year veteran of the biotechnology industry and has held Health Economics responsibilities for Smith & Nephew and Covance Health Economics & Outcomes Services (previously Corning Inc.).
-- Kathy McGee, who joined the Company in May 2006 when ABH purchased Dermagraft(R) and TransCyte(R) from Smith and Nephew Wound Management LLC, has been promoted to Vice President and General Manager (La Jolla facility). McGee has been involved with these products for over 17 years and is a globally recognized expert in the manufacture and distribution of cell-based products. Previously, she served as Director of Manufacturing Operations at Smith & Nephew, and was instrumental in renovating and revalidating ABH's manufacturing facility. Prior to joining Smith & Nephew, McGee held several positions in Manufacturing and Quality Control at Advanced Tissue Sciences. (McGee explains the manufacture, science and safety of Dermagraft in video interviews on the ABH website.)
-- Keith O'Briant, formerly ABH's Vice President of Sales, has been named the Company's new Senior Vice President of North American Sales. O'Briant, who built the Company's sales force to over 80 professionals in nine regional teams during the past three years, is now responsible for accelerating the recruitment and training of a North American sales team that will include over 100 professionals by year-end 2009. A veteran of healthcare commercialization, O'Briant held a variety of commercial and sales leadership positions within Pfizer. (O'Briant shares more about building the ABH sales team and his talent strategy in a video on the ABH website.)
-- Dean Tozer, responsible for creating ABH's initial commercialization strategy, has been promoted to Senior Vice President. In this position, he will oversee ABH's marketing, corporate development, reimbursement, government affairs and product development. Tozer joined the Company in 2006 as Vice President of Marketing and Corporate Development. A former independent consultant to the biopharmaceutical industry, Tozer also spent 10 years in the global pharmaceutical arena and was a commercial team lead for the global launch of Celebrex. He also held a variety of management positions with G.D. Searle, a division of Monsanto. (Tozer discusses future growth for ABH and opportunities for Dermagraft in video interviews on the ABH website.)
"The promotions of Theresa, Kathy, Keith and Dean come at an inflection point for ABH as we continue to accelerate commercialization of Dermagraft in the U.S., while also expanding its potential clinical applications," said Kevin Rakin, Chairman and Chief Executive Officer. "Each of these individuals has played a critical role in developing an infrastructure that supports more than 1,000 advanced wound care centers and outpatient offices throughout North America. They are now tasked with supporting a strategic plan that calls for continued growth of our U.S. sales and expanding Dermagraft's utility in other areas of regenerative medicine."
About Advanced BioHealing, Inc.
Advanced BioHealing develops and commercializes living cell technologies that repair damaged human tissue and enable the body to heal itself. A privately held company with more than 200 employees, Advanced BioHealing maintains corporate offices in Westport, CT and a 70,000 sq. ft. manufacturing facility in La Jolla, CA. To meet Advanced BioHealing's executives and learn more about the Company, please visit the Company's web site at www.ABH.com.
SOURCE: Advanced BioHealing, Inc. (ABH)
Advanced BioHealing Lindsey Hart Direct: 773-697-3838 Cell: 206-335-0114 lhart@abh.com or Gregory FCA Kristy DelMuto Direct: 610-228-2118 Cell: 484-686-4775 Kristy@GregoryFCA.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
